Early detection of diabetic neuropathy
SUDOSCAN efficacy in early detection of diabetic neuropathy has been demonstrated in several studies, wich helps for a better management of diabetes complications sush as diabetic foot and cardiac autonomic neuropathy and follow up disease progression.
Why control diabetic
complications
How to reduce diabetic foot risk and cardiovascular complications
Diabetic foot
Loss of autonomous innervation affects peripheral microvascular perfusion. It ultimately results in dry skin, loss of sweating and the development of fissures and cracks leading to infectious ulcers and gangrene [6]. In the long run, amputation and foot ulceration are the most common consequences of peripheral diabetic neuropathy and major causes of morbidity and disability. Every 30 seconds a lower limb is lost to diabetes somewhere in the world and up to 70 % of all leg amputations are due to the same cause. Currently available methods used to detect distal peripheral neuropathy rely on assessment of irreversible damage to the large nerve fibers. The commonly used tests (sensation (pinprick, monofilament), vibration sensation, pressure sensation) are subjective and offer poor reproducibility.
Cardiovascular complications
Cardiovascular Autonomic Neuropathy (CAN) is the clinically most critical form of diabetic autonomic neuropathy. It is caused by a loss of autonomous cardiac innervation and results in diminished Heart Rate Variability (HRV) and vascular dynamics. Detecting Cardiovascular Autonomic Neuropathy early can help prevent sudden cardiac death and myocardial infarction [6-7]. Heart Rate Variability has proven to be a predictor for all-cause mortality but is time consuming and requires specific diagnostic equipment [7].
SUDOSCAN is a quick and non-invasive test to early detect diabetic peripheral neuropathy.
SUDOSCAN Benefits
Fast
No patient preparation
Results in 3 minutes
Easy-to-read critical data points to help physicians reach a diagnosis
Secure
Non-invasive
No fasting
Easy to operate
CE and FDA approvals
Accurate
Reproducible quantitative results
Independent from environmental conditions
Backed by evidence-based research
150 peer-reviewed journals publications
References
[1] American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2007; 30(suppl):S4-S41.
[2] Deedwania PC, Fonseca VA. Diabetes, prediabetes and cardiovascular risk: shifting the paradigm. Am J Med. 2005; 11:939-947.
[3] DECODE Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003; 26(3):688-696.
[4] Weissmann PN. Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. Am J Cardiol. 2002; 90(suppl):42G-50G.
[5] National Diabetes Statistics fact sheet, NIIDDK, 2007.
[6] Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic Autonomic Neuropathy. Diabetes Care 2003; 26:1553-1579.
[7] Vinik AI, Ziegler D. Diabetic Cardiovascular Autonomic Neuropathy. Circulation 2007; 115:387-397.[8] Selvarajah D et al (Tesfaye S). Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. The Lancet Diab & Endoc, Volume 7, Issue 12, December 2019, 938-948.